Spots Global Cancer Trial Database for solid malignancies
Every month we try and update this database with for solid malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children | NCT00695370 | Solid Malignanc... | Pegfilgrastim (... | - 18 Years | University Hospital, Clermont-Ferrand | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) | NCT00751894 | Solid Malignanc... | Pegfilgrastim (... | - 18 Years | University Hospital, Clermont-Ferrand | |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | NCT00388427 | Malignant Solid... | Dasatinib (BMS-... Cetuximab (Erbi... | 18 Years - | University of Pittsburgh | |
| A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients | NCT00613652 | Cancer Tumors Carcinoma | AZD4877 | 20 Years - 75 Years | AstraZeneca | |
| Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | NCT00753740 | Cancer Ovarian Cancer Solid Tumor | IT-101 (12mg/m2... IT-101 (15mg/m2... 5% Dextrose (Pl... | 18 Years - 78 Years | Lumos Pharma | |
| Safety Study of CALAA-01 to Treat Solid Tumor Cancers | NCT00689065 | Cancer Solid Tumor | CALAA-01 | 18 Years - | Calando Pharmaceuticals | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children | NCT00695370 | Solid Malignanc... | Pegfilgrastim (... | - 18 Years | University Hospital, Clermont-Ferrand | |
| Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | NCT00753740 | Cancer Ovarian Cancer Solid Tumor | IT-101 (12mg/m2... IT-101 (15mg/m2... 5% Dextrose (Pl... | 18 Years - 78 Years | Lumos Pharma | |
| Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor | NCT01024283 | Advanced Solid ... | 16 Years - | Royal Marsden NHS Foundation Trust | ||
| Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies | NCT00389480 | Tumors | AR-67 (formerly... | 18 Years - | Arno Therapeutics | |
| Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | NCT05902520 | HNSCC Melanoma Gynecologic Can... Colorectal Canc... Lung Cancer Urogenital Canc... | DP CD8 TIL DP CD8 TIL KD Low dose IL-2 | 18 Years - | AgonOx, Inc. | |
| Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | NCT01540526 | Solid Malignanc... Metastatic Cast... | axitinib | 18 Years - | University of Wisconsin, Madison | |
| Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors | NCT00389389 | Neoplasms | AZD4877 | 18 Years - | AstraZeneca | |
| A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | NCT01300533 | Metastatic Canc... Cancer Solid Tumors | BIND-014 | 18 Years - | BIND Therapeutics | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | NCT05902520 | HNSCC Melanoma Gynecologic Can... Colorectal Canc... Lung Cancer Urogenital Canc... | DP CD8 TIL DP CD8 TIL KD Low dose IL-2 | 18 Years - | AgonOx, Inc. | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | NCT01300533 | Metastatic Canc... Cancer Solid Tumors | BIND-014 | 18 Years - | BIND Therapeutics | |
| To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies | NCT05866354 | Solid Malignanc... | Tisotumab Vedot... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies | NCT05866354 | Solid Malignanc... | Tisotumab Vedot... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies | NCT01202370 | Solid Malignanc... | 7-t-butyldimeth... | 18 Years - | University of Kentucky | |
| Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. | NCT00162136 | Solid Malignanc... | Ixabepilone | 18 Years - | R-Pharm | |
| A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies | NCT01202370 | Solid Malignanc... | 7-t-butyldimeth... | 18 Years - | University of Kentucky | |
| A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies | NCT01202370 | Solid Malignanc... | 7-t-butyldimeth... | 18 Years - | University of Kentucky | |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | NCT05006794 | Solid Malignanc... | GS-9716 Docetaxel sacituzumab gov... | 18 Years - | Gilead Sciences | |
| Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors | NCT00389389 | Neoplasms | AZD4877 | 18 Years - | AstraZeneca | |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | NCT00473616 | Advanced Solid ... Cancer Advanced Solid ... | AZD7762 Irinotecan | 18 Years - | AstraZeneca | |
| Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. | NCT00162136 | Solid Malignanc... | Ixabepilone | 18 Years - | R-Pharm | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | NCT00473616 | Advanced Solid ... Cancer Advanced Solid ... | AZD7762 Irinotecan | 18 Years - | AstraZeneca | |
| Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | NCT02537418 | Solid Malignanc... | durvalumab tremelimumab | 18 Years - | Canadian Cancer Trials Group | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours | NCT01112397 | Solid Malignanc... | AZD1480 | 18 Years - | AstraZeneca | |
| Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | NCT00894894 | Solid Tumors | MP-470 amuvatinib (MP-... | 18 Years - 70 Years | Astex Pharmaceuticals, Inc. | |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | NCT00388427 | Malignant Solid... | Dasatinib (BMS-... Cetuximab (Erbi... | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
